New hope for heart patients: pelacarsen available through special program
NCT ID NCT07000695
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides access to pelacarsen, a drug for atherosclerotic cardiovascular disease, for patients who have no other treatment options and cannot join a clinical trial. It is for those with serious or life-threatening conditions where the potential benefit outweighs the risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pelacarsen
What this could lead to
If successful, this program could provide access to a new treatment option for patients with serious heart disease who have no other alternatives.
What could go wrong
This is not a clinical trial but a managed access program, so data on effectiveness and safety is limited. The drug may not work for everyone and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact